文献速递病毒性肝炎

冷藏缺血期间使用亚甲蓝处理移植物可降低丙型肝炎病毒传播风险

Methylene Blue Treatment of Grafts During Cold Ischemia Time Reduces the Risk of Hepatitis C Virus Transmission.
PubMed 文献 · J Infect Dis · 2018-01-01

该概念验证研究探讨在冷藏缺血期间用亚甲蓝(MB)处理丙型肝炎病毒(HCV)RNA阳性供肾能否减少HCV传播。体外实验中仅MB在所有保存液中完全灭活HCV;微型猪污染肾经MB冲洗联合低温机器灌注后对移植物无不良影响,人肝-uPA-SCID小鼠接种灌流液后未建立HCV感染。

要点

  • 体外实验中,仅亚甲蓝在所有灌注保存液中完全灭活HCV。
  • 微型猪HCV污染肾经亚甲蓝联合低温机器灌注处理,对移植物无不良影响。
  • 人肝-uPA-SCID小鼠接种处理肾灌流液后未建立HCV感染。

核心结论

  • 该概念验证研究是减少移植场景中感染性HCV颗粒传播的第一步,并可能作为其他相关病原体的模型。

研究设计与样本

  • 研究采用标准病毒学检测方法,在体外评估包括亚甲蓝在内的抗病毒药物在不同保存液中对HCV的作用。
  • 用Jc1或HCV RNA阳性人血清污染微型猪肾脏,随后用亚甲蓝冲洗器官,并采用低温机器灌注以优化HCV的减少。
  • 将处理肾脏的灌流液接种至人肝-uPA-SCID小鼠以评估HCV感染建立情况。

主要发现

  • 体外评估三种不同抗病毒药物灭活HCV的能力,仅亚甲蓝在所有灌注保存液存在下完全灭活HCV。
  • 微型猪HCV污染肾经亚甲蓝和低温机器灌注处理,对移植物无任何不良影响。
  • 人肝-uPA-SCID小鼠接种这些肾脏的灌流液后未建立HCV感染。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Although organ shortage is a rising problem, organs from hepatitis C virus (HCV) ribonucleic acid (RNA)-positive donors are not routinely transplanted in HCV-negative individuals. Because HCV only infects hepatocytes, other organs such as kidneys are merely contaminated with HCV via the blood. In this study, we established a protocol to reduce HCV virions during the cold ischemic time. METHODS: Standard virological assays were used to investigate the effect of antivirals, including methylene blue (MB), in different preservation solutions. Kidneys from mini pigs were contaminated with Jc1 or HCV RNA-positive human serum. Afterwards, organs were flushed with MB. Hypothermic machine perfusion was used to optimize reduction of HCV. RESULTS: Three different antivirals were investigated for their ability to inactivate HCV in vitro. Only MB completely inactivated HCV in the presence of all perfusion solutions. Hepatitis C virus-contaminated kidneys from mini pigs were treated with MB and hypothermic machine perfusion without any negative effect on the graft. Human liver-uPA-SCID mice did not establish HCV infection after inoculation with flow through from these kidneys. CONCLUSIONS: This proof-of-concept study is a first step to reduce transmission of infectious HCV particles in the transplant setting and might serve as a model for other relevant pathogens.

来源:J Infect Dis,查看原文。版权归原作者所有。

引用

  1. Helfritz FA, Bojkova D, Wanders V, et al. Methylene Blue Treatment of Grafts During Cold Ischemia Time Reduces the Risk of Hepatitis C Virus Transmission. J Infect Dis. 2018. PMID: 29939277. doi:10.1093/infdis/jiy386

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。